[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:t-14-16":3},{"name":4,"total":5,"recruiting":6,"trials":7},"t(14;16)",3,2,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05776979","Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients",[12],"Phase 2","RECRUITING","2026-08-26T02:19:19.162260Z","2026-05-05T02:43:29.189075Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05469893","Immuno-PRISM (PRecision Intervention Smoldering Myeloma)",[12],"2026-08-26T02:18:55.570428Z","2026-05-05T02:43:27.482255Z",{"nct_id":23,"title":24,"phases":25,"status":26,"updated_at":27,"content_modified":28},"NCT07029776","MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma",[12],"NOT_YET_RECRUITING","2026-08-26T02:18:08.005333Z","2026-05-05T02:43:28.128103Z"]